

Pamela Bell, BS²; Thelma Dangana, MBBS, MS²; Galina Sidimirova, BSN⁵; Robert A. Weinstein, MD, FIDSA, FSHEA²; Louis Fogg, PhD²; Michael Y. Lin, MD, MPH²; Vincent B. Young, MD, PhD⁶; Mary K. Hayden, MD⁷ and The CDC Prevention Epicenter Program; ¹Internal Medicine/Infectious Diseases, University of Michigan, Ann Arbor, Michigan; ²Rush University Medical Center, Chicago, Illinois; ³Medical Laboratory Science, Rush University Medical Center, Chicago, Illinois; ⁴Infectious Disease, University of Tokyo Hospital, Tokyo, Japan; ⁵Infection Control, Rush Oak Park Hospital, Oak Park, Illinois; ⁶Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan; ⁷Department of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois

Session: 214. Host-pathogen Integration
Saturday, October 7, 2017: 8:30 AM

Background. Colonization with KPC-Kp precedes infection and represents a potential target for intervention. To identify microbial signatures associated with KPC-Kp acquisition, we conducted a prospective, longitudinal study of the fecal microbiota in LTACH patients at risk of acquiring KPC-Kp.

Methods. We collected admission and weekly rectal swab samples from patients admitted to one LTACH from May 2015 to May 2016. Patients were screened for KPC-Kp by PCR at each sampling time. KPC acquisition was confirmed by culture of KPC-Kp. To assess changes in the microbiota related to acquisition, we sequenced the 16S rRNA gene (V4 region) from collected rectal swabs. Diversity, intra-individual changes, and the relative abundance of the operational taxonomic unit (OTU) that contains KPC-Kp were compared in patients who were KPC-Kp negative upon admission and who had at least one additional swab sample collected.

Results. 318 patients (1247 samples) were eligible for analysis; 3.7 samples (mean) were collected per patient. Sixty-two patients (19.5%) acquired KPC-Kp (cases) and 256 patients remained negative for all carbapenem-resistant Enterobacteriaceae throughout their stay (controls). Median length of stay before KPC-Kp detection was 14.5 days. At time of KPC-Kp acquisition, levels of an Enterobacteriaceae OTU increased significantly compared with pre-acquisition samples and to samples from control patients (Wilcoxon test, $P < 0.0001$). Similarly, we observed a decrease in total diversity of the fecal microbiota at time of acquisition in cases ($P < 0.01$). Compared with controls, cases exhibited decreased intra-individual fecal microbiota similarity immediately prior to acquisition of KPC-Kp ($P < 0.01$). Comparison of microbial features at time of admission using random forest revealed a higher abundance of *Enterococcus* and *Escherichia* OTUs in controls vs cases.

Conclusion. We observed intra-individual changes in the fecal microbiota of case patients prior to acquisition of KPC-Kp. Compared with patients who did not acquire KPC-Kp, cases exhibited significant changes in microbiota diversity and increased abundance of potential KPC-Kp at acquisition. Our results suggest that shifts in the microbiota may precede colonization by KPC-Kp.

Disclosures. N. M. Moore, Cepheid: Research Contractor, Funded and provided reagents for associated research projects; R. A. Weinstein, OpGen: Receipt of donated laboratory services for project, Research support; CLorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; M. Y. Lin, Sage, Inc.: receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; OpGen, Inc.: receipt of in-kind laboratory services, Conducting studies in healthcare facilities that are receiving contributed product; M. K. Hayden, OpGen, Inc.: Receipt of donated laboratory services for project, Research support; Clorox: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Molnlycke: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product; Sage Products: Receipt of contributed product, Conducting studies in healthcare facilities that are receiving contributed product.

1768. Reduction in the Prevalence of Healthcare-Associated Infections in U.S. Acute Care Hospitals, 2015 vs 2011

Shelley S. Magill, MD, PhD¹; Lucy E. Wilson, MD, ScM²; Deborah L. Thompson, MD, MSPH³; Susan M. Ray, MD, FIDSA^{4,6}; Joelle Nadle, MPH⁷; Ruth Lynfield, MD, FIDSA⁸; Sarah J. Janelle, MPH, CIC⁹; Marion A. Kainer, MBBS, MPH, FSHEA¹⁰; Samantha Greissman, MPH¹¹; Ghinwa Dumyati, MD, FSHEA¹²; Zintars G. Beldavs, MS¹³; Jonathan R. Edwards, MStat¹ and Emerging Infections Program Hospital Prevalence Survey Team; ¹Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia; ²Maryland Department of Health and Mental Hygiene, Baltimore, MD; ³Presbyterian Healthcare Services, Albuquerque, New Mexico; ⁴New Mexico Department of Health, Santa Fe, New Mexico; ⁵Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia; ⁶Georgia Emerging Infections Program, Decatur, Georgia; ⁷California Emerging Infections Program, Oakland, California; ⁸Minnesota Department of Health, St. Paul, Minnesota; ⁹Colorado Department of Public Health and Environment, Denver, Colorado; ¹⁰Tennessee Department of Public Health, Nashville, Tennessee; ¹¹Connecticut Emerging Infections Program, Hartford and New Haven, Connecticut; ¹²New York Emerging Infections Program at the University of Rochester Medical Center, Rochester, New York; ¹³Oregon Health Authority, Portland, Oregon

Session: 215. National Trends in HAIs
Saturday, October 7, 2017: 8:30 AM


Background. A 2011 prevalence survey conducted by CDC and the Emerging Infections Program (EIP) showed that 1 in 25 hospital patients had ≥ 1 healthcare-associated infection (HAI). We repeated the survey in 2015 to assess changes in HAI prevalence.

Methods. In EIP sites (CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) hospitals that participated in the 2011 survey were recruited for the 2015 survey. Hospitals selected 1 day from May–September 2015 on which a random patient sample was identified from the morning census. Trained EIP staff reviewed patient medical records using comparable methods and the same National Healthcare Safety Network HAI definitions used in 2011. Proportions of patients with HAIs were compared using chi-square tests; patient characteristics were compared using chi-square or median tests (OpenEpi 3.01, SAS 9.3).

Results. Data were available from 143 hospitals that participated in both surveys; data from 8954 patients in the 2011 survey were compared with preliminary data from 8833 patients in the 2015 survey. Patient characteristics such as median age, days from admission to survey, and critical care location were similar. Urinary catheter prevalence was lower in 2015 (1,589/8,833, 18.0%) compared with 2011 (2,052/8,954, 22.9%, $P < 0.0001$), as was central line prevalence (2015: 1,539/8,833, 17.4%, vs. 2011: 1,687/8,954, 18.8%, $P = 0.02$). The proportion of patients with HAIs was lower in 2015 (284/8,833, 3.2%, 95% confidence interval [CI] 2.9–3.6%) than in 2011 (362/8,954, 4.0%, 95% CI 3.7–4.5%, $P = 0.003$). Of 309 HAIs in 2015, pneumonia (PNEU) and *Clostridium difficile* infections (CDI) were most common (Figure); proportions of patients with PNEU and/or CDI were similar in 2015 (130/8833, 1.5%) and 2011 (133/8954, 1.5%, $P = 0.94$). A lower proportion of patients had surgical site (SSI) and/or urinary tract infections (UTI) in 2015 (77/8833, 0.9%) vs. 2011 (136/8954, 1.5%, $P < 0.001$).

Conclusion. HAI prevalence was significantly lower in 2015 compared with 2011. This is partially explained by fewer SSI and UTI, suggesting national efforts to prevent SSI, reduce catheter use and improve UTI diagnosis are succeeding. By contrast, there was no change in the prevalence of the most common HAIs in 2015, PNEU and CDI, indicating a need for increased prevention efforts in hospitals.

Figure: Prevalence and Distribution of HAIs, 2011 vs. 2015



Disclosures. All authors: No reported disclosures.

1769. Assessing The Impact of The National Healthcare Safety Network's (NHSN's) New Baseline on Acute Care Hospital Standardized Infection Ratios (SIRs)

Minn Soe, MBBS, MPH; Allan Nkwata, MPH; Jonathan R. Edwards, MStat; Margaret Dudeck, MPH, CPH and Daniel Pollock, MD; Centers for Disease Control and Prevention, Atlanta, Georgia

Session: 215. National Trends in HAIs
Saturday, October 7, 2017: 8:30 AM

Background. To more accurately measure the progress of healthcare-associated infection (HAI) prevention efforts, the CDC's National Healthcare Safety Network (NHSN) surveillance system updated risk-adjustment models for computation of updated Standardized Infection Ratios (SIRs), the primary HAI summary measure by NHSN. This study sought to examine how the updated SIRs varied from the previous SIRs calculated using older baselines for acute care hospital HAIs.

Methods. We analyzed NHSN data for healthcare facility-onset laboratory-identified *Clostridium difficile* [CDI] and methicillin-resistant *Staphylococcus aureus* [MRSA] bacteremia reported in accordance with the CMS' inpatient quality reporting program requirement. The unit of analysis was CMS certification number (CCN) facility reporting in 2015. We compared overall distributions of CCN-level SIRs (CCN-SIRs) between new risk-adjustment models using a 2015 baseline (SIR_NEW) and old models using a 2011 baseline (SIR_OLD) and tested location shift (median away from null) of pairwise differences. We also examined the magnitude of shift in SIR from old to new baseline.

Results. For each HAI, the national pooled mean SIR of the new baseline was ~ 1.0 . For CDI, the overall distributions of CCN SIR_NEW and CCN-SIR_OLD were different, and the median of pairwise difference was away from null with CCN-SIR_NEW slightly higher. For MRSA, the SIR differences were not significant. Most CCN-SIRs (83% for CDI, 93% for MRSA) remained in the same significance category across the old and new baselines ("worse," "better," "not different from national benchmark"), and few CCN-SIRs were reclassified to a less favorable category. For 75% of

CCN-SIRs, their relative position in the quartile distributions of SIR_NEW and SIR_OLD remained the same. The discrepancies between SIR_NEW and SIR_OLD tended to be larger among CCNs with high SIRs.

Conclusion. The updated national pooled mean SIRs were close to 1.0, validating the potential use of new risk adjustment models and baseline as updated benchmarks for tracking CDI and MRSA prevention progress. The shifts in CCN-level SIRs between old and new baselines were not large, indicating a modest impact of new baselines at the CCN level, except among hospitals with high SIRs.

TABLE 1: Comparisons of the NHSN HAI standardized infection ratios (SIRs) between new and old baselines

	Metrics	CDI	MRSA
National pooled mean SIR			
NEW baseline (SIR_NEW)	HCN facility reporting, mean	3810, 0.997	3753, 1.013
OLD baseline (SIR_OLD)	HCN facility reporting, mean	3810, 0.931	3753, 0.962
Distribution of CCN-LEVEL SIR			
NEW baseline	HCN with SIR available, mean, median (IQR)	3047, 0.96 0.92 (0.60)	1710, 1.01 0.85 (0.91)
OLD baseline	HCN with SIR available, mean, median (IQR)	3298, 0.82 0.80 (0.62)	1845, 0.99 0.82 (0.95)
Comparison of overall distributions of CCN-LEVEL SIRs between OLD and NEW baseline			
	Kolmogorov-Smirnov test p-value	<0.0001	0.3487
Pairwise comparison of CCN-LEVEL SIRs among CCNs with available SIRs across OLD and NEW baseline			
		N=3041	N=1694
SIR Difference (SIR_NEW - SIR_OLD)	mean, median (IQR)	0.11, 0.07 (0.17)	0.005, 0.00 (0.21)
Test if median of pairwise differences is away from null	p-value by Sign test	<0.0001	0.1568
Change in significance level of CCN-level SIR from OLD to NEW baseline			
No change*	HCN (%)	2519 (83%)	1568 (93%)
Change into less favorable direction**	HCN (%)	424 (14%)	73 (4%)
Magnitude of shift in CCN-level SIR from OLD to NEW baseline			
Shift within the same quartile	HCN (%)	2215 (73%)	1267 (75%)
Shift up or below but within 1 quartile	HCN (%)	762 (25%)	218 (13%)

*CCN with "not different from national benchmark" (NS) in SIR_OLD remains NS in SIR_NEW; CCN with "worse than national benchmark" (WORSE) in SIR_OLD remains WORSE in SIR_NEW; CCN with "better than national benchmark" (BETTER) in SIR_OLD remains BETTER in SIR_NEW.
 **CCN with "not different from national benchmark" in SIR_OLD becomes "worse than national benchmark" in SIR_NEW; CCN with "better than national benchmark" in SIR_OLD becomes "WORSE than national benchmark" in SIR_NEW; CCN with "better than national benchmark" in SIR_OLD becomes "not different from national benchmark" in SIR_NEW.

Figure 1: Facility-onset laboratory-identified Clostridium difficile infection: (1-A) Comparison of overall distributions of CCN-level SIRs between new and old baseline, (1-B) Pairwise difference of CCN-level SIRs between new and old baseline, (1-C) Agreement plot that compares CCN-level SIRs between new and old baseline





Figure 2: Facility-onset laboratory-identified MRSA bacteremia infection: (2-A) Comparison of overall distributions of CCN-level SIRs between new and old baseline, (2-B) Pairwise difference of CCN-level SIRs between new and old baseline, (2-C) Agreement plot that compares CCN-level SIRs between new and old baseline



Disclosures. All authors: No reported disclosures.

1770. Wide Range of Carbapenem-resistant Enterobacteriaceae Incidence and Trends in Emerging Infections Program Surveillance, 2012–2015

Nadezhda Duffy, MD, MPH¹; Cedric J. Brown, MS¹; Sandra N. Bulens, MPH¹; Wendy Bamberg, MD²; Sarah J. Janelle, MPH, CIC³; Jesse T. Jacob, MD^{3,4}; Chris Bower, MPH^{5,6}; Lucy Wilson, MD⁶; Elisabeth Vaeth, MPH⁶; Ruth Lynfield, MD, FIDSA⁷; Paula Snippes Vagnone, MT (ASCP)⁷; Erin C. Phipps, DVM, MPH⁸; Emily B. Hancock, MS⁹; Ghinwa Dumyati, MD, FSHEA¹⁰; Cathleen Concannon, MPH¹¹; Zintars G. Beldavs, MS¹²; P. Maureen Cassidy, MPH¹²; Marion Kainer, MBBS, MPH, FSHEA¹³; Daniel Muleta, MD, MPH¹³; Isaac See, MD¹; ¹Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia; ²Colorado Department of Public Health and Environment, Denver, Colorado; ³Georgia Emerging Infections Program, Decatur, Georgia; ⁴Emory University School of Medicine, Atlanta, Georgia; ⁵Atlanta Veterans Affairs Medical Center, Decatur, Georgia; ⁶Maryland Department of Health and Mental Hygiene, Baltimore, Maryland; ⁷Minnesota Department of Health, St. Paul, MN; ⁸University of New Mexico, New Mexico Emerging Infections Program, Albuquerque, New Mexico; ⁹New Mexico Emerging Infections Program, University of New Mexico, Albuquerque, New Mexico; ¹⁰Center for Community Health, University of Rochester Medical Center, Rochester, New York; ¹¹NY Emerging Infections Program, Center for Community Health, University of Rochester Medical Center, Rochester, New York; ¹²Oregon Health Authority, Portland, Oregon; ¹³Tennessee Department of Health, Nashville, Tennessee

Session: 215. National Trends in HAIs

Saturday, October 7, 2017: 8:30 AM


Background. Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent threat in the United States because of high morbidity and mortality, few treatment options, and potential for rapid spread among patients. To assess for changes in CRE epidemiology and risk among populations, we analyzed CDC Emerging Infections Program (EIP) 2012–2015 surveillance data for CRE.

Methods. Active, population-based CRE surveillance was initiated in January 2012 at 3 EIP sites (GA, MN, OR) and expanded to 5 additional sites (CO, MD, NM, New York, TN) by 2014. An incident case was the first *Escherichia coli*, *Enterobacter*, or *Klebsiella* isolate (non-susceptible to at least one carbapenem and resistant to all third-generation cephalosporins tested) collected from urine or a normally sterile body site from a patient during a 30-day period. Data were collected from patients' medical records. Cases were hospital-onset (HO) or long-term care facility (LTCF) onset if patients were in the respective facility ≥3 days prior to culture or at the time of culture; and community-onset (CO) otherwise. We calculated incidence rates based on census data for EIP sites and described by type of infection onset.

Results. A total of 1,582 incident CRE cases were reported in 2012–2015. Most cases (88%) were identified through urine cultures; 946 (60%) were female, and median age was 66 years (interquartile range: 55–77). The median incidence by site was 2.95 per 100,000 population (range: 0.35–8.98). Among the three sites with four full years of data, a different trend was seen in each (Figure). Trends in GA and MN were statistically significant, and no significant trend was seen in OR. Overall, 480 cases (30%) were HO, 524 (33%) were LTCF onset, and 578 (37%) were CO. Of CO cases, 308 (53%) had been hospitalized, admitted to a long-term acute care hospital or were a LTCF resident in the prior year.

Conclusion. CRE incidence varied more than 20-fold across surveillance sites, with evidence of continued increases in MN. Measuring impact of programs aimed at reducing CRE transmission in other regions will require obtaining local data to identify cases occurring during and after healthcare facility discharge. Further study of changes in incidence in some settings and areas might offer opportunities to refine and expand effective control strategies.

CRE Incidence by EIP Site, 2012-2015



Disclosures. All authors: No reported disclosures.

1771. The Effect of National Healthcare Safety Network (NHSN) Rebaselining on Community Hospital SIRs

Christopher Hostler, MD, MPH^{1,2,3}; Rebekah W. Moehring, MD, MPH^{1,2,3}; Arthur W. Baker, MD, MPH^{1,4}; Becky Smith, MD^{1,2}; Linda Adcock, RN, BSN, CIC¹; Brittain Wood, RN, BSN, CIC¹; Evelyn Cook, RN, CIC¹; Linda Crane, BSMT(SM), CIC¹; Andrea Cromer, RN, CIC¹; Kathy Lockamy, RN, CIC¹; Susan Louis, RN, CIC¹; Polly Padgett, RN, BSN, CIC¹; Christopher W. Woods, MD, MPH, FIDSA^{2,3}; Daniel Sexton, MD⁴; Deverick Anderson, MD, MPH, FSHEA, FIDSA^{1,2} and Sarah S. Lewis, MD MPH^{1,2}; ¹Duke Center for Antimicrobial Stewardship and Infection